Rocket Pharmaceuticals

company

About

Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$100.30M
Industries
Biotechnology,Genetics,Health Care,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:RCKT
Legal Name
Rocket Pharmaceuticals, Inc.
Also Known As
Rocket Pharmaceuticals Ltd.

Rocket Pharmaceuticals is a biotechnology company that is working to develop first-in-class gene therapy treatments for rare and undertreated diseases. The Company's lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult-to-treat genetic disease that causes bone marrow failure and, in the worst-case scenario, cancer. Additional bone marrow-derived disorders are being studied in preclinical trials, including Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1), and Infantile Malignant Osteopetrosis. In addition, the company is working on an AAV-based gene therapy program for an unnamed rare pediatric disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
11
$653.05M
Rocket Pharmaceuticals has raised a total of $653.05M in funding over 2 rounds. Their latest funding was raised on Oct 3, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 3, 2022 Post-IPO Equity $100.30M Detail
Aug 30, 2021 Post-IPO Equity $26.40M 1 RTW Investments Detail
Dec 9, 2020 Post-IPO Equity $299M 1 Detail
Nov 13, 2020 Grant $3.70M 1 California Institute of Regenerative Medicine (CIRM) Detail
Dec 10, 2019 Post-IPO Equity $84.99M Detail

Investors

Number of Lead Investors
Number of Investors
3
5
Rocket Pharmaceuticals is funded by 5 investors. RTW Investments and California Institute of Regenerative Medicine (CIRM) are the most recent investors.
Investor Name Lead Investor Funding Round
RTW Investments Yes Post-IPO Equity
California Institute of Regenerative Medicine (CIRM) Yes Grant
Frazier Healthcare Partners Post-IPO Equity
Civilization Ventures Post-IPO Equity
Sahsen Ventures Post-IPO Equity

Employee Profiles

Number of Employee Profiles
10
Rocket Pharmaceuticals has 10 current employee profiles, including Executive Gaurav Shah
Executive
Executive
Executive
Executive
Executive

Acquisition

Rocket Pharmaceuticals has acquired 2 organizations. Their most recent acquisition was Inotek Pharmaceuticals on Sep 12, 2017. They acquired Inotek Pharmaceuticals for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition Detail
Sep 20, 2022 Renovacor
Biotechnology acquisition Detail